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Anti-Stx2 Antibody
Kristin A. D. Sauter,1 Angela R. Melton-Celsa,2 Kay Larkin,3 Megan L. Troxell,3
Alison D. O’Brien,2 and Bruce E. Magun1*
Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, Oregon 972391; Department of
Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 208142; and
Department of Pathology, Oregon Health and Science University, Portland, Oregon 972393
Received 14 May 2008/Returned for modification 16 June 2008/Accepted 25 July 2008
Hemolytic-uremic syndrome (HUS) results from infection by Shiga toxin (Stx)-producing Escherichia coli
and is the most common cause of acute renal failure in children. We have developed a mouse model of HUS
by administering endotoxin-free Stx2 in multiple doses over 7 to 8 days. At sacrifice, moribund animals
demonstrated signs of HUS: increased blood urea nitrogen and serum creatinine levels, proteinuria, deposition
of fibrin(ogen), glomerular endothelial damage, hemolysis, leukocytopenia, and neutrophilia. Increased ex-
pression of proinflammatory chemokines and cytokines in the sera of Stx2-treated mice indicated a systemic
inflammatory response. Currently, specific therapeutics for HUS are lacking, and therapy for patients is
primarily supportive. Mice that received 11E10, a monoclonal anti-Stx2 antibody, 4 days after starting
injections of Stx2 recovered fully, displaying normal renal function and normal levels of neutrophils and
lymphocytes. In addition, these mice showed decreased fibrin(ogen) deposition and expression of proinflam-
matory mediators compared to those of Stx2-treated mice in the absence of antibody. These results indicate
that, when performed during progression of HUS, passive immunization of mice with anti-Stx2 antibody
prevented the lethal effects of Stx2.
Hemolytic-uremic syndrome (HUS) results from infection
by Shiga toxin (Stx)-producing Escherichia coli (STEC), most
commonly serotype O157:H7, and is the most common cause
of acute renal failure in children (for reviews, see references
15, 40, 42, and 46). Accumulated evidence points to endothe-
lial cell damage as the hallmark of HUS-associated thrombotic
microangiopathy, which is characterized by fibrin deposition
within small vessels, swelling of glomerular endothelial cells,
and thrombotic occlusion of capillaries (17). Severe cases of
HUS exhibit renal cortical necrosis, pervasive inflammatory
cell infiltrates in the kidney, and apoptosis of renal and cortical
glomerular and tubular cells (20, 23, 55, 62).
STEC expresses either Stx1 or Stx2, which is usually encoded
by bacteriophages. Each Shiga holotoxin consists of one A and
five B subunits. The B subunit binds to cells via glycosphingo-
lipid receptors such as globotriaosyl ceramide (Gb3), while the
A subunit contains N-glycosidase activity (5, 30). Following
endocytosis and retrograde transport through the Golgi appa-
ratus, the A subunit enters the cytosol. There, it depurinates a
single adenine (A4256 in mice) in a conserved region of the
28S rRNA, thereby inhibiting protein synthesis (9, 10, 36, 49)
and simultaneously activating the stress-activated protein ki-
nases (SAPKs) Jun N-terminal kinase (JNK) and p38 (4, 13,
53). Stxs and ricin, a related ribotoxin, induce the release of
proinflammatory cytokines and activate the transcription of
genes that encode them (27, 37, 40, 43, 48). Activation of
SAPKs by Stx and ricin has been tied to their proinflammatory
effects (4, 27).
Although administration of intravenous Stx to primates has
been able to reproduce the features of HUS (52), the devel-
opment of an HUS model in small animals has been less
successful (2, 44). The inability of Stx to reproduce glomeru-
lopathy in animal models may be due to the variable distribu-
tion of receptors for Stx among species (29). In view of the
availability of mice containing null mutations in a variety of
proinflammatory and regulatory genes, a mouse model of HUS
using Stx alone that reproduces the manifestations of human
disease would be valuable. The primary impediment to the
development of a murine model of HUS has been the inability
of investigators to produce glomerular thrombotic microangi-
opathy (TMA), which is a hallmark of human HUS. Bacterial
endotoxin, or lipopolysaccharide (LPS), has been employed in
combination with Stx2 to reproduce the signs of HUS (3, 22,
24). However, LPS has been shown to either reduce or en-
hance Stx toxicity, depending on the time and dose of admin-
istration (38). For example, pretreatment with LPS protects
animals from the effects of Stx, whereas LPS administered 8 or
24 h but not 0 or 72 h after challenge with Stx enhances the
toxicity (3). Mortality rates and cytokine production in mice
remained unchanged after administration of various concen-
trations of Stx in combination with sublethal doses of LPS at
various times (54). Ikeda et al. found that LPS, when admin-
istered at the appropriate time, was essential for induction of
HUS; however, this model lacked the typical hemolytic ane-
mia. (19). Keepers et al. developed another murine model
using Stx and LPS; however, some of the signs, such as lym-
* Corresponding author. Mailing address: Department of Cell and
Developmental Biology, Oregon Health and Science University, 3181
SW Sam Jackson Park Rd., Portland, OR 97239. Phone: (503) 494-
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phocytopenia and neutrophilia, were transient, lasting only a
few hours (24).
Currently, specific therapeutics for HUS are lacking, and
therapy for HUS patients is primarily supportive. Although
diagnostic reagents have recently been developed for early
detection of Stx (57), and antibodies (Abs) (chimeric, human-
ized, and fully human) have been developed for potential pas-
sive immunization (6, 8, 28, 34, 35), it is unclear whether
administration of anti-Stx therapeutics would be effective when
performed after signs have developed in humans, though these
Abs are protective after infection with STEC in a mouse model
of infection (50, 64). Stx that is bound to polymorphonuclear
leukocytes was detected for up to 1 week after diagnosis in the
circulation of patients who had developed HUS (58). This
suggests that delayed delivery of toxin to the microvasculature
over an extended time may contribute to the clinical signs of
HUS (58). For these reasons, passive immunization with anti-
Stx2 Ab following the appearance of initial signs may block the
development of clinical signs and alleviate disease in patients
who have been diagnosed with HUS (60).
In the present studies, we have developed a model of HUS
in mice by administering multiple sublethal doses of Stx2, in
the absence of LPS, over a period of 7 to 8 days. Administra-
tion of a mouse monoclonal Ab (11E10) directed against Stx2
was able to halt the lethality and reverse the manifestations of
HUS when Ab was delivered as late as 4 days after the initial
exposure to Stx2. These data suggest that, in this model of
murine HUS, Stx2-mediated renal failure required extended
exposure and that administration of anti-Stx2 Ab midway
through the course of administration interfered with an other-
wise lethal outcome.
MATERIALS AND METHODS
Mice. C57BL/6J mice were purchased from The Jackson Laboratory, Bar
Harbor, ME. Male mice aged 8 to 10 weeks of age and weighing 18 to 24 g were
used throughout the experiments. Mice were housed under a 12-hour light-dark
cycle and fed a standard diet ad libitum. Groups of mice were injected intra-
peritoneally with 50 l of either saline, Stx2, or Stx2 plus 11E10 antibody as
follows: (i) saline (control solvent) on days 0, 3, and 6; (ii) 5 ng Stx2/20 g of body
weight (bwt) on day 0; (iii) 1 ng Stx2/20 g bwt on days 0, 3, and 6; or (iv) 1 ng
Stx2/20 g bwt on days 0, 3, and 6 plus 30 ng 11E10 Ab/20 g bwt on day 4. Mice
were weighed on day 0 and every day thereafter. To collect 24-hour urine, mice
were housed for 24 to 48 h in “diuresis metabolic cages” (model M-D-METAB;
Nalgene, Braintree, MA) and provided with a ground standard diet ad libitum.
Before experimental procedures, mice were anesthetized intraperitoneally with
80 mg ketamine/kg of body weight and 10 mg/kg xylazine. All of the animal
procedures were performed according to protocols that have been approved by
the Institutional Animal Care and Use Committee at Oregon Health and Science
University, Portland, OR.
Reagents and Abs. The mouse monoclonal anti-Stx2 Ab (11E10) has been
previously described (41). Ab against fibrin/fibrinogen (YNGMFbg7S) was pur-
chased from Accurate Chemical and Scientific (Westbury, NY). Stx2 was pro-
duced in E. coli DH5 using the pLPSH3 plasmid and purified by immunoaffinity
chromatography as previously described (33). When examined by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the toxin prepara-
tion exhibited the expected bands representing the A, A1, and B subunits. In
addition, the specific activity of the toxin for Vero cells was 1  107 50%
cytotoxic doses per g. Stx2 was dissolved in 0.9% endotoxin-free saline (Braun
Medical Inc.). Levels of endotoxin were undetectable, as determined with a
Limulus amebocyte assay (Cambrex).
Mouse blood studies. All blood analyses were performed by IDEXX Labora-
tories (Portland, OR). Mice were euthanized, and blood was collected. Whole
blood for cell count analysis and cell type determination was collected in hema-
tology tubes with tripotassium EDTA (Microtainer; Becton Dickinson, Franklin
Lakes, NJ). In addition, total blood was left to coagulate at room temperature for
10 min, after which samples were centrifuged at 8,000 rpm and 4°C for 10 min
and serum was collected. Biochemical determinations of blood urea nitrogen
(BUN) and serum creatinine levels were performed.
Proteinuria studies. Mice were housed in “diuresis metabolic cages” for 24 to
48 h, during which time urine was collected. Equal amounts of urine from each
mouse were further concentrated through 30-kDa Micropore concentration
tubes. Urine samples were mixed 1:2 with 4 SDS-PAGE loading buffer and
boiled at 95°C for 5 min. Samples from each group of three mice were pooled
and separated via 10% SDS-PAGE. Gels were stained with Gelcode Blue stain-
ing solution. Bovine serum albumin was loaded on the same gel as a positive
control.
Spectrophotometric determination of hemoglobin levels in serum. Total blood
was left to coagulate at room temperature for 10 min, after which samples were
centrifuged at 8,000 rpm and 4°C for 10 min. Two microliters of serum was used
to obtain an absorption spectrum in a Nano Drop spectrophotometer (Nano
Drop, Wilmington, DE).
Immunohistochemistry. Mice were anesthetized and sacrificed by cervical
dislocation. The kidneys were dissected, fixed in Carnoy solution for 2 h, and
transferred to 70% ethanol. The organs were embedded in paraffin blocks and
sectioned into 5-m sections. After blocking in serum, the slides were incubated
with primary Abs overnight at 4°C at appropriate dilutions. Slides were further
processed using the VectaStain Elite ABC kit (Vector Laboratories, Burlingame,
CA) according to the manufacturer’s recommendations using 3,3-diaminoben-
zidine as substrate. Photomicrographs of immunohistochemical preparations in
Fig. 2A and 7A were taken at a1,000 magnification at identical exposure times.
Detection of tissue fibrin(ogen) by immunoblotting. Fibrin(ogen) deposition
in kidneys was detected as described previously (63). Frozen kidneys were ho-
mogenized in 10 mM sodium phosphate buffer (pH 7.5) containing 5 mM EDTA,
100 mM ε-aminocaproic acid, 10 U/ml heparin, and 2 mM phenylmethylsulfonyl
fluoride. The homogenate was incubated for 18 h on a top-over-top rotor at 4°C.
After centrifugation (10,000 rpm, 4°C, 10 min), the pellet was resuspended in the
same 10 mM sodium phosphate buffer as above, without phenylmethylsulfonyl
fluoride, and recentrifuged. Pellets were resuspended in 3 M urea, agitated for
2 h at 37°C, and centrifuged at 14,000 rpm at 4°C for 15 min. The pellets were
resuspended in reducing SDS sample buffer (10 mM Tris [pH 7.5], 5% glycerol,
2% SDS, 5% -mercaptoethanol, and 0.4 mg/ml bromophenol blue) and dis-
solved at 65°C for 90 min with vortexing every 15 min. Samples were subjected
to SDS-PAGE (7.5%; 5% stacking gel) and transferred to a polyvinylidene
difluoride membrane. Fibrin chains were detected with a fibrin(ogen) Ab and a
chemiluminescence system. Fibrin standards were prepared by clotting a known
amount of rat fibrinogen (Sigma) with an excess of human thrombin (Sigma) at
37°C for 10 min. After 2 SDS sample buffer was added, the standards were
incubated at 65°C for 90 min.
Electron microscopy. After dissection of the kidneys, tissue was fixed and
processed using standard procedures, including immediate fixation in 2.5% glu-
taraldehyde in sodium phosphate buffer for 2 hours, postfixation in osmium
tetroxide, and embedding in plastic resin. Thick sections (1 m) were stained
with toluidine blue, and ultrathin sections were stained with uranyl acetate and
lead citrate. Photomicrographs were taken at 11,000 magnification.
RNA isolation. After dissection of the kidneys, the tissue was immediately
frozen and ground in liquid nitrogen. RNA was extracted using TRIzol reagent
in accordance with the manufacturer’s instructions and was further digested with
DNase. Both reagents were purchased from Invitrogen Life Technologies, Carls-
bad, CA.
Real-time PCR analysis. Two micrograms of RNA was reverse transcribed in
the presence of SuperScript II and oligo(dT) primers (both reagents were pur-
chased from Invitrogen Life Technologies). The amplification of the cDNA was
accomplished in an ABI Prism 7900HT sequence detection system (Applied
Biosystems, Foster City, CA) in the presence of the commercially available Sybr
green PCR Master Mix (Applied Biosystems) and 20 mol/liter of the corre-
sponding sense and antisense reverse transcription-PCR (RT-PCR) primers for
120-bp amplicons in a 40-cycle PCR. Each sample was analyzed in triplicate.
Induction in gene expression was measured using absolute quantitation of a
standard curve in arbitrary units. The denaturing, annealing, and extension
conditions of each PCR cycle were 95° for 15 s, 55° for 30 s, and 72° for 30 s,
respectively. The SDS software was used for normalization of the raw data. The
nucleotide sequences of primers used in this study have been previously pub-
lished (28).
Reverse transcription of rRNA by primer extension. Reverse transcription of
rRNA was performed as described by Iordanov and colleagues (21). The oligo-
nucleotide primer 5-CACATACACCAAATGTC-3 (Invitrogen Life Technol-
ogies) was end labeled with T4 polynucleotide kinase (Life Technologies, Inc.).
A 10-l mixture of 2 g total RNA and 1.0 pmol primer in 50 mmol/liter
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Tris-HCl (pH 8.3)–75 mmol/liter KCl–3 mmol/liter MgCl2 was incubated at 90°C
for 3 min and then placed on ice for 5 min, followed by an incubation at room
temperature for 5 min. The reverse transcription was initiated by the addition of
10 l of a mixture of 2 mmol/liter deoxynucleoside triphosphates and 30 U
SuperScript (Life Technologies, Inc.) in 50 mmol/liter Tris-HCl (pH 8.3), 75
mmol/liter KCl, 3 mmol/liter MgCl2, 10 mmol/liter dithiothreitol, followed by an
incubation at 48°C for 15 min, when the reactions were stopped by the addition
of 5 mmol/liter EDTA. Reaction products were precipitated in ethanol, resus-
pended in formamide gel loading buffer, heat denatured, and electrophoresed in
an 8% acrylamide sequencing gel, which was subsequently dried and exposed to
a PhosphorImager screen.
Multiplex cytokine detection. Serum samples were analyzed using a custom-
ized multiplex mouse cytokine kit from Linco Research (St. Charles, MO) and
detected on the LiquiChip workstation (Qiagen, Valencia, CA). Each sample
was analyzed in duplicate.
Statistical analysis. Individual groups were compared using unpaired t test
analysis. To estimate P values, all statistical analyses were interpreted in a
two-tailed manner. P values of 0.05 were considered statistically significant.
RESULTS
To examine the consequences of Stx2 administered intra-
peritoneally to C57BL/6J mice, we first determined the toxicity
of Stx2 when administered as a single dose. Dose-response
experiments determined that the 50% lethal dose was 3 ng
Stx2/20 g bwt (data not shown). In initial experiments, admin-
istration of a lethal dose of Stx2 (a single dose of 5 ng Stx2/20
g bwt, hereafter referred to as “1x5”) resulted in weight loss
detected 24 h later, which continued for 3 days (Fig. 1A). At
that time, animals were moribund, having lost at least 20% of
their bwt and displaying tremors and ataxia. For ethical rea-
sons, these mice were euthanized on the third day following
injection of Stx2. BUN levels from these animals increased
from 31  6.3 to 103.8  36.6 mg/dl (P  0.05), but creatinine
levels failed to differ significantly (Fig. 1B). Urine from these
animals failed to show signs of albuminuria, an indicator of
renal failure, as determined by PAGE (Fig. 1C). The presence
of hemoglobin in serum was evaluated by determining the
absorbance spectrum of serum. Mice receiving 1x5 Stx2
showed an increased spectral absorbance profile characteristic
of free hemoglobin (7) (Fig. 1D). Animals receiving 1x5 Stx2
failed to show an increase in circulating neutrophils, although
they exhibited a significant decrease in circulating lymphocytes
(Fig. 1E). From these data, we concluded that administration
FIG. 1. Analysis of bwt, blood parameters, and urine after administration of Stx2 to mice. Groups of mice were injected with Stx2 or saline as
follows: (i) 1x5, a single injection of 5 ng Stx2/20 g bwt at t  0; (ii) 3x1, three injections of 1 ng Stx2/20 g bwt at t  0, t  3 days, and t  6 days;
and (iii) saline (S), three injections of 50 l saline at t 0, t 3 days, and t 6 days. (A) Percent total bwt loss in mice injected with Stx2 or saline.
Mouse weight at day 0 was set at 100%. Data reflect five mice per group  standard deviations. *, P  0.05; **, P  0.01. (B) Measurement of
BUN and creatinine levels in sera. Each circle represents the measurement of BUN or creatinine level from one mouse; black bars represent the
means of samples in each group. Brackets indicate levels of significance between groups: *, P  0.05; **, P  0.01; ***, P  0.001. (C) Presence
of protein in urine of mice following administration of Stx2 or saline. Equal amounts of pooled urine from groups of three saline-injected, 1x5,
and 3x1 mice were separated by SDS-PAGE. Bovine serum albumin (3 g) was used as a standard for albumin. MM, molecular mass.
(D) Measurement of hemoglobin by absorption spectrophotometry of sera. Absorption spectrophotometry of sera from two saline-injected, 1x5,
and 3x1 mice demonstrate absorbance maxima at 430 nm and 575 nm, characteristic of hemoglobin. (E) Measurement of neutrophil and
lymphocyte numbers. Each circle represents the measurement of neutrophil or lymphocyte numbers from one mouse; black bars represent the
means of samples in each group. Brackets indicate levels of significance between groups: *, P  0.05; **, P  0.01; ***, P  0.001.
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of 1x5 Stx2 triggered some hemolysis and a modest impairment
of renal function, as evidenced by increased BUN levels, but
failed to induce other significant signs of renal dysfunction,
such as increased creatinine and proteinuria levels.
Signs of HUS in humans usually do not appear earlier than
1 week following exposure to STEC (60). We considered,
therefore, that mice may require an extended time interval
between initial exposure to Stx2 and the development of signs
of HUS. First, we investigated whether lower doses of Stx2 that
allowed mice to survive for at least 1 week would permit the
animals to develop more-severe manifestations of HUS, in-
cluding renal failure. However, single doses of Stx2 lower than
5 ng/20 g bwt that permitted animals to survive more than 3
days were ineffective in inducing either toxicity or signs of renal
failure (not shown). We then tested whether administration of
successive, lower doses of Stx2 over an extended time course
would permit the animals to develop signs characteristic of
HUS in humans. When we administered two injections of 1 ng
Stx2/20 g bwt (at days 0 and 3), mice showed minor signs of
toxicity and renal failure when sacrificed 8 days later (data not
shown). We then injected animals with three doses of 1 ng
Stx2/20 g bwt at day 0, day 3, and day 6 (hereafter referred to
as “3x1”). The mice receiving 3x1 Stx2 did not begin to lose
significant bwt until day 5 (Fig. 1A). By day 7 or 8, these mice
had lost a total of 20 to 25% of their initial bwt and were
euthanized. Unlike mice receiving 1x5 Stx2, these animals did
not exhibit neurological signs at time of sacrifice. BUN levels
increased nearly sixfold (P  0.001) in the 3x1 Stx2 mice, while
creatinine levels increased 2.5-fold (P  0.01) compared to
those of saline-injected control mice (Fig. 1B). The urine of the
3x1 Stx2 mice displayed increased protein content with a major
protein band corresponding in size to serum albumin and ad-
ditional bands of proteins with higher molecular weight (Fig.
1C). The increased serum levels of BUN and creatinine and
the appearance of proteinuria suggested that administration of
3x1 Stx2 resulted in compromised renal function. Furthermore,
spectrophotometric analysis of serum from these mice revealed
hemolysis, as evidenced by levels of hemoglobin in the serum
that were greater than that seen in 1x5 animals (Fig. 1D).
Unlike the 1x5 mice, the 3x1 mice exposed for 7 to 8 days
developed increased numbers of circulating neutrophils (from
738.8  83.1 cells/l in control mice to 1,047.6  223.8 cells/ml
in Stx2-treated mice [P  0.05]) and decreased numbers of
lymphocytes (from 3,779.6  767.1 cells/ml in control mice
to 566  327.9 cells/ml in Stx2-treated mice [P  0.001])
(Fig. 1E).
Glomerular TMA is a distinguishing feature of human HUS
that has been difficult to recreate in animal models. Compared
with those from animals treated with saline, kidneys from mice
receiving 1x5 Stx2 showed a small amount of fibrin(ogen) de-
position in glomerular vessels, as demonstrated by both antifi-
brin(ogen) immunohistochemistry (Fig. 2A) and immuno-
blotting (Fig. 2B). However, mice injected with 3x1 Stx2
demonstrated abundant deposition of fibrin(ogen) in the glo-
merular capillary loops, with some capillaries appearing to be
completely occluded (Fig. 2A). The deposition of increased
fibrin(ogen) in kidneys from these mice was confirmed by im-
munoblotting (Fig. 2B). Transmission electron microscopy of
kidneys from two 3x1 Stx2 animals revealed enlarged suben-
dothelial zones (asterisk, Fig. 3B) containing flocculent mate-
rial (so called subendothelial “fluff”) with accompanying en-
dothelial cell cytoplasmic swelling and loss of fenestrae (area
delimited by bracket). Subtle mesangiolysis was also seen fo-
cally (data not shown). Kidneys from 1x5 Stx2-treated animals
showed similar but less pronounced alterations in morphology
of glomeruli (data not shown).
Inflammatory responses. We next analyzed RNA from
mouse kidneys by real-time RT-PCR, to determine the effects
of Stx2 on the expression of mRNA transcripts that encode
proteins implicated in inflammatory responses. Groups of five
mice injected with 1x5 Stx2 or 3x1 Stx2 were sacrificed on day
3 or day 7, respectively. Animals receiving saline alone were
sacrificed on day 7. The transcripts evaluated included cy-
FIG. 2. Detection of fibrin/fibrinogen by immunohistochemistry
and immunoblotting. Groups of five mice were injected with Stx2 or
saline as described for Fig. 1. From each mouse, one half-kidney
was fixed and embedded for immunohistochemistry and the other
half was homogenized in lysis buffer for immunoblotting. Immuno-
histochemistry and immunoblotting were performed on each kidney
specimen. (A) Immunohistochemical detection of fibrin/fibrinogen.
The photomicrograph displayed in this figure is representative of
immunohistochemical reactivity. Bar, 20 m. (B) Detection of fi-
brin/fibrinogen by immunoblotting. The volume of lysis buffer em-
ployed for extraction was adjusted for the weight of each half-
kidney. Following preparation of the lysate, 50 l was separated by
electrophoresis and transferred to a membrane for immunoblotting
with antifibrin(ogen) as described in Materials and Methods. The
procedure for preparation of kidney lysates has been described in
Materials and Methods. The immunoblot in this figure is represen-
tative of the five independent lysates that were examined. MM,
molecular mass.
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tokines (tumor necrosis factor alpha [TNF-	], interleu-
kin-1	 [IL-1	], IL-1, and IL-6), chemokines (CCL2/
monocyte chemoattractant protein 1 and CXCL1/Gro-	),
transcription factors (c-Jun, c-Fos, and EGR1), and a sur-
face adhesion protein (intercellular adhesion molecule 1).
The results were expressed as increase in RNA expression in
Stx2-treated animals over that of saline controls, using glycer-
aldehyde phosphate dehydrogenase mRNA as a control to
standardize the samples (Fig. 4A). The administration of ei-
ther 1x5 or 3x1 Stx2 significantly elevated the expression of the
majority of transcripts investigated. The expression levels of
two gene transcripts, CXCL1/Gro-	 and IL-6, were signifi-
cantly greater in the 3x1 Stx2-treated mice than in the 1x5
Stx2-treated mice.
We employed a customized multiplex mouse cytokine kit
to measure the expression of several proinflammatory cyto-
kines and chemokines in the serum of mice treated with
saline or Stx2. Administration of either 1x5 or 3x1 Stx2
significantly elevated the levels of all proinflammatory pro-
teins investigated compared to those in saline-injected con-
trol mice (Fig. 4B). However, levels of these proteins in sera
from 1x5 and 3x1 mice did not differ significantly from each
other (Fig. 4B). The data shown in Fig. 4B suggest that the
Stx2-induced increase in expression of transcripts encoding
proinflammatory cytokines and chemokines was associated
with an increased level of corresponding proteins in the
serum. Importantly, these data indicated that the induced
expression of proinflammatory mRNAs associated with Stx2
intoxication resulted in the synthesis of proteins directed by
those mRNAs, even in the face of potentially decreased
levels of protein synthesis that may occur following Stx2-
induced damage to 28S rRNA.
FIG. 3. Transmission electron microscopy of glomeruli from saline-injected (A) and 3x1 (B) mice. Groups of two mice were injected with either
Stx2 or saline as described for Fig. 1. The asterisk in panel B indicates enlarged subendothelial space. The bracketed area delimits the portion of
endothelium that has lost fenestrae. Bar, 1 m.
FIG. 4. Measurement of proinflammatory gene products in mouse
kidneys and sera. Groups of mice were injected with Stx2 or saline as
described for Fig. 1. In addition, a group of 3x1 mice was injected with
11E10 on day 4 (gray bars). (A) Measurement of RNA transcripts by
quantitative real-time RT-PCR. Kidney RNA was analyzed from five
animals per group (saline, 1x 5, 3x1, or 3x1 plus 11E10). Each bar
represents the mean increase in RNA expression  standard error of
the mean compared with values obtained from control saline-injected
mice. Brackets indicate levels of significance between groups: *, P 
0.05; **, P  0.01; ***, P  0.001. (B) Measurement of cytokines and
chemokines in sera from groups of three mice. Sera were analyzed
from three animals per group (saline, 1x5, 3 x1, or 3x1 plus 11E10).
Each bar represents the mean value of each protein  standard devi-
ation. Brackets indicate levels of significance between groups: *, P 
0.05; **, P  0.01; ***, P  0.001.
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Stx2-mediated lesions in 28S rRNA. Stx2 may impair kidney
function by acting directly on cells of the kidney and/or indi-
rectly by inducing the release of inflammatory mediators into
the systemic circulation from body tissues. To determine the
existence of damage to renal 28S rRNA specifically caused by
Stx2, we applied primer extension analysis, a technique that
produces truncated radiolabeled transcripts at the site of de-
purination (A4256) in 28S rRNA (21). RNA extracted from
the kidneys of mice exposed to 1x5 Stx2 displayed the strongest
lesion-specific signals (Fig. 5). Lesions in A4256 were also
observed in the 3x1 Stx2 mice but were diminished in amount
compared with lesions produced by 1x5 Stx2. These results
indicated that a single dose of 5 ng Stx2 produced more lesions
in renal 28S rRNA than did three successive injections of 1 ng
Stx2.
Passive immunization by anti-Stx2 Ab. To determine
whether administration of anti-Stx2 Ab could prevent pro-
gression of HUS in our model, we administered 11E10, a
monoclonal Ab, to mice exposed to 3x1 Stx2. For mice
receiving three injections of 1 ng Stx2/20 g bwt (on days 0, 3,
and 6), we injected a single bolus of 30 ng 11E10 Ab/20 g bwt
at different times prior to sacrifice at day 7 to 8. All mice
that received Ab on day 4 did not develop subsequent weight
loss and appeared normal at time of sacrifice on day 8 (Fig.
6A). However, when Ab was administered to mice on day 5,
rescue of some, but not all, mice was achieved (data not
shown). Administration of Ab on day 6 failed to rescue any
mice (data not shown). To determine whether mice receiv-
ing Ab on day 4 would develop impaired kidney function, we
evaluated levels of BUN and serum creatinine at day 8 (2
days after mice received the final dose of 1 ng Stx2/20 g bwt).
Levels of BUN and serum creatinine in these mice were not
different from those in saline-injected control animals (Fig.
6B). In addition, the level of free hemoglobin appearing in
sera of 3x1 mice was not increased in the sera of 3x1 Stx2
mice receiving 11E10 Ab on day 4 (Fig. 6C), suggesting that
administration of anti-Stx2 Ab to the 3x1 Stx2 mice pre-
vented intravascular hemolysis. The neutrophilia and lym-
phocytopenia normally present in 3x1 Stx2 mice were not
present in 3x1 mice receiving anti-Stx2 Ab on day 4 (Fig.
6D). In addition, the administration of 3x1 Stx2 and 11E10
Ab on day 4 reduced the deposition of fibrin(ogen) in kid-
neys harvested at 8 days, as determined by both immuno-
histochemistry and immunoblotting (Fig. 7A and B).
The administration of 11E10 Ab on day 4, in concert with
3x1 Stx2, significantly decreased the expression of the majority
of proinflammatory mRNA transcripts that were investigated
in the kidneys. Expression of most transcripts decreased by
more than 50% compared to kidneys from 3x1 mice that did
not receive 11E10 Ab (Fig. 4A). There was also a coordinate
decrease in abundance of circulating proinflammatory proteins
in sera from these mice compared with mice that had received
3x1 Stx2 alone (Fig. 4B). 3x1 mice receiving 11E10 Ab on day
FIG. 5. Detection of lesions at A4256 in 28S rRNA by primer extension. Groups of mice were injected with Stx2 or saline as described for Fig.
1. Total RNA was purified from kidneys of four or five mice per group. Each lane represents a different mouse. Truncated transcripts at A4256
were detected from all Stx2-treated mouse kidneys (middle arrow).
FIG. 6. Analysis of bwt and blood parameters after administration
of Stx2 with or without 11E10. Mice received saline, the 3x1 treatment,
or the 3x1 treatment plus 11E10 (mouse monoclonal Ab against Stx2)
on day 4. (A) Weight loss in mice injected with Stx2 with or without
11E10. Each bar represents the mean value for five mice  standard
deviation. (B) Measurement of BUN and creatinine levels in sera.
Data for saline-injected (triangles) and 3x1 (squares) mice have been
shown in Fig. 1B; these are included here for comparison with the 3x1
plus 11E10 group. Data are the averages of five mice  standard
deviations. Each circle for 3x1 plus 11E10 represents one mouse; black
bars indicate the means of samples for the group. Brackets indicate
levels of significance between groups: *, P  0.05; **, P  0.01; ***,
P  0.001. (C) Measurement of hemoglobin by absorption spectro-
photometry of sera. Absorption spectrophotometry of sera from two
saline-injected, 3x1, and 3x1 plus 11E10 mice. (D) Measurement of
neutrophil and lymphocyte numbers. Data for saline-injected (trian-
gles) and 3x1 (squares) mice have been shown in Fig. 1E; these are
included here for comparison with the 3x1 plus 11E10 group. Data
represent the averages of five mice  standard deviations. Each circle
for 3x1 plus 11E10 represents one mouse; black bars indicate the
means of samples for the group. Brackets indicate levels of significance
between groups: *, P  0.05; **, P  0.01; ***, P  0.001.
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4 remained healthy and displayed normal renal function at the
time of sacrifice 4 weeks later (data not shown).
DISCUSSION
Stx is the main etiologic factor in the pathogenesis of HUS
(40). Although the administration of Stx alone to primates
reproduces signs of HUS (52), Stx alone has not been able to
produce the majority of HUS signs in small-animal models.
The development of a murine model of HUS would provide an
economic advantage for therapeutic experimentation and, in
view of the ready availability of mouse strains that are deficient
in key mediators of inflammatory or coagulatory processes,
would further offer the benefit of employing the power of
mouse genetics. Although the coadministration of LPS and Stx
has been able to reproduce many of the signs of HUS in a
murine model (24), these data are controversial because LPS is
not required to produce HUS in a primate model (52) and
because the required presence of LPS in humans with HUS
remains undefined. Furthermore, LPS has been shown to ei-
ther reduce or enhance Stx toxicity in murine models, depend-
ing on the time and dose of administration (38). In this study,
we have sought to develop a mouse model of HUS by admin-
istering endotoxin-free Stx2.
Administration of a single lethal dose of Stx2 to mice in-
duced hemolysis, lymphocytopenia, and modest impairment of
renal function, as evidenced by increased BUN levels at 72 h.
Although the lethal dose of Stx2 produced modest renal dys-
function, it was not able to generate many of the significant
indicators of renal failure, such as increased creatinine and
proteinuria levels. Mice exposed to a single bolus (5 ng/20 g
bwt) of Stx2 developed tremors and ataxia prior to death,
indicating that the early demise of these mice may have re-
sulted from toxicity for the nervous system. Stx binds to Gb3
receptors in neurons of the central nervous system of mice (26)
and has been found to produce brain damage in mice (25).
Neurological damage in humans is a frequent complication in
HUS (32, 51, 61) and in experimental animals (rabbits) ex-
posed to Stx (14, 56). We reasoned that administration of a
lower dose of Stx2 may allow the mice to survive for a longer
period of time, permitting them to develop a symptomatic
course that would more completely reproduce the character-
istics of HUS. Although administration of low doses of Stx2 in
a single or double injection was ineffective in producing the
array of signs that characterizes HUS, the administration of
three successive injections of 1 ng Stx2/20 g bwt at 72-h inter-
vals resulted in the development of many of the manifestations
of HUS that develop in humans. The 3x1 mice began losing
weight 4 days after the initial injection and, at the time of
sacrifice (7 to 8 days), manifested increased BUN, serum cre-
atinine, and proteinuria levels, all of which are indicators of
compromised renal function. In addition, these mice devel-
oped hemolysis, lymphocytopenia, and neutrophilia, unlike
mice that received saline alone. It should be noted that, al-
though analysis of the above indicators was performed at dif-
ferent times in 1x5 mice than in 3x1 mice, the animals at the
time of sacrifice had undergone a comparable loss of bwt.
Injury of the endothelium contributes to the development of
microvascular thrombosis, a common feature of HUS that has
been tied to development of renal failure in human patients
(40, 42, 43). Endothelial cell injury and thrombosis have been
difficult to reproduce in Stx-induced animal models (38, 39, 47,
59). The degree of fibrin(ogen) deposition in glomerular cap-
illaries was greater in 3x1 than in 1x5 mice; some capillaries in
the 3x1 mice appeared to be completely occluded (Fig. 2).
Furthermore, examination of kidneys from multiply Stx2-in-
jected mice by electron microscopy revealed subtle focal
mesangiolysis, subendothelial “fluff,” endothelial cell cytoplasmic
swelling, and loss of fenestrae. These characteristics are com-
monly observed in HUS in humans.
Abundant evidence suggests that Stx-induced HUS involves
an acute inflammatory response, the magnitude of which is a
predictor of clinical outcome. Patients with HUS display mark-
edly elevated levels of proinflammatory cytokines such as
FIG. 7. Detection of fibrin/fibrinogen by immunohistochemistry
and immunoblotting after administration of Stx2 with or without
11E10. Groups of mice were injected as described for Fig. 6. (A) Im-
munohistochemical detection of fibrin/fibrinogen. Bar, 20 m. (B) De-
tection of fibrin/fibrinogen by immunoblotting. MM, molecular mass.
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TNF-	 and IL-1 and chemokines (45) such as CCL2/mono-
cyte chemoattractant protein 1, CXCL8/IL-8, CXCL1/Gro-	,
and CXCL3/Gro-
 (31, 37, 40, 42). Excretion of urinary TNF-	
and IL-6 is elevated during the acute phase of HUS in patients
(D. Karpman, A. Andreasson, H. Thyssell, B. S. Kaplan, and C.
Svanborg, presented at the Second International Symposium
and Workshop on Verocytotoxin-Producing Escherichia coli
Infections, Bergamo, Italy, 1994). Stx has been shown to stim-
ulate the release of proinflammatory cytokines from several
types of cultured cells, including macrophages (12), renal
podocytes (18), and human vascular endothelial cells (16).
Increased expression of proinflammatory transcripts and the
presence of proinflammatory chemokines and cytokines in the
sera of Stx2-treated mice provided evidence that these animals
developed an abundant inflammatory response. At the time of
death, expression of circulating proinflammatory mediators
was similar in singly and multiply injected mice, suggesting that
the development of multiple manifestations of HUS may re-
quire an extended exposure to these circulating mediators.
Depurination of a single adenine (A4256 in mice) in a con-
served region of the 28S rRNA by Stx is similar to that per-
formed by ricin, a related toxin (11), and is the single known
mechanism by which the toxins transduce their signals follow-
ing entrance into cells (21). This event leads not only to inhi-
bition of protein translation but also to the rapid activation of
SAPKs, p38 and JNK, by activating kinases situated upstream
in the activating cascade (21, 53). Activation of SAPKs and the
subsequent increased production of proinflammatory tran-
scripts occur in the presence of only partial translational inhi-
bition (27). As a consequence, increased levels of transcribed
proinflammatory mRNA molecules are capable of being trans-
lated into functional proteins (27). Importantly, the present
study shows that, similarly to ricin, the Stx2-induced expression
of proinflammatory mRNAs resulted in the synthesis of proin-
flammatory proteins, despite potentially decreased levels of
protein synthesis. However, this study does not address
whether the cells directly targeted by Stx2 are the ones that
secrete the proinflammatory proteins that appear in sera. The
increased appearance of proinflammatory proteins may occur
secondarily in response to signals initiated in cells that have
internalized the Stx2. The 1x5 and 3x1 mice expressed similar
levels of proinflammatory transcripts and protein products at
their respective times of sacrifice (Fig. 4). However, because
analysis of expressed gene products was performed at different
times in the two groups (3 days versus 7 to 8 days), the course
of expression of mRNA or protein over the exposure interval
for each group of mice remains unknown. We postulate that,
although 3x1 mice were exposed to a smaller amount of Stx2
than were 1x5 mice, the increased time of exposure over the
longer period was responsible in large part for the develop-
ment of proinflammatory consequences and renal failure.
Detection of lesions in rRNA by primer extension analysis
showed that the accumulated damage in 1x5 mice at 72 h was
greater than that in 3x1 mice, suggesting that the development
of Stx2-mediated renal failure may require an extended time to
permit the animals to develop signs characteristic of HUS. In
human disease, 10 to 15% of infected individuals progress to
HUS 1 week after the initial onset of signs (1). Our results
suggest that the administration of small, multiple injections of
Stx2 may reproduce the development of HUS that occurs in
humans over an extended period of time.
To determine whether administration of an anti-Stx2 Ab
would prevent progression of HUS in our mouse model, we
administered 11E10, a specific monoclonal Ab that recog-
nizes the A subunit of Stx2, at various times after the second
dose of 1 ng Stx2/20 g bwt. 3x1 mice receiving 11E10 on day
4 showed normal renal function and normal neutrophil and
lymphocyte levels and lacked hemolysis at the time of sac-
rifice. In addition, these mice showed decreased fibrin(ogen)
deposition compared to that of Stx-treated mice in the ab-
sence of Ab. The inflammatory response, as determined by
measurement of proinflammatory transcripts in the kidney
and demonstration of protein in the sera, was reduced by
more than 50% in proinflammatory mRNAs and proteins
that were examined. Taken together, these results indicate
that passive immunization with anti-Stx2 Ab in mice was
capable of preventing the lethality of the toxin, even after
initial exposure to Stx and in the continued presence of
circulating Stx.
Current treatment of HUS in patients is supportive, and
effective therapeutic intervention has not been successful (1,
60). Our results suggest that passive immunization against Stx
may be therapeutically effective in humans at risk of develop-
ing HUS, if Ab is able to be administered at an early time
after development of signs and before the accumulated
effects of HUS have resulted in irreversible structural
damage.
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